Home › Companies › BIOA

BioAge Labs, Inc.

BIOA Lead: Phase 1 1 Biotech Distilled article ↓

Most recent annual filing: 2026-03-24

Pipeline (2 active programs)

BGE-102

Small Molecule Target: NLRP3

Technology platforms

BioAge Longevity Map · Eli Lilly and Company

Human aging biology target discovery platform combining longitudinal multi-omic molecular profiling of aging cohorts with data science analysis to identify novel drug targets for cardiometabolic and metabolic diseases; focus on chronic cardiometabolic diseases

BioAge Longevity Map · Novartis Pharma AG

Human aging biology target discovery platform; ongoing target discovery collaboration with Novartis focused on identifying novel cardiometabolic disease targets

Discontinued (1)

azelaprag — Obesity · terminated due to liver transaminitis observations in some patients in the azelaprag arms of the STRIDES Phase 2 clinical trial

Biotech Distilled coverage (1)

2026-05-18 BioAge Labs (BIOA) - Scientific Deep Dive for BGE-102 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.